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The Jak-Stat-Socs pathway is an important component of cytokine receptor signaling. Not
surprisingly, perturbation of this pathway is implicated in diseases of hematopoietic and
immune origin, including leukemia, lymphoma and immune deficiencies. This review examines
the role of a key component of this pathway, Stat5. This has been shown to be activated in a
variety of leukemias and myeloproliferative disorders, including downstream of a range of key
oncogenes where it has been shown to play an important role in mediating their effects.
Therefore, Stat5 represents a useful pan-leukemia/myeloproliferative disorder diagnostic
marker and key therapeutic end point, as well as representing an attractive therapeutic target
for these disorders.
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Jak-Stat-Socs pathway 
The Jak-Stat-Socs pathway represents an evolu-
tionarily conserved signaling module widely
engaged by growth factor and cytokine recep-
tors to rapidly facilitate changes in gene expres-
sion in response to appropriate external stimu-
lus [1–4]. Thus, the binding of many cytokines
or growth factors to their cognate cell surface
receptor triggers dimerization and structural
changes in the receptor complex, which leads
to the activation of one or more members of
the Jak family of protein tyrosine kinases,
which are prebound to the cytoplasmic domain
of the receptor. This results in autophosphor-
ylation of adjacent Jak proteins as well as phos-
phorylation of the receptor. The resultant
phosphotyrosine residues on the receptor (and
Jak) then serve as docking sites for members of
the Stat family of transcription factors. These
then become tyrosine phosphorylated, form-
ing either homo- or heterodimeric complexes
that translocate to the nucleus and bind to the
promoter region of responsive genes to activate
their transcription. Target genes include the
Socs family of proteins (Socs1–7 and Cis),
which generally act as a negative feedback sys-
tem via direct competition of Stat binding,
inhibition of Jak kinase activity or degradation
of active receptor complexes [3,5–7].
Stat5 proteins
Mammals possess two Stat5 proteins, Stat5a
and Stat5b, which have 96% homology and are
encoded by adjacent genes [8]. These proteins
were first identified as prolactin (PRL)-induced
mammary gland factor that produced tissue-
specific and hormonally controlled transcrip-
tion of the β-casein gene promoter. [9]. It is
now known that Stat5 proteins are activated by
a wide range of cytokine receptors (TABLE 1) [1].
This includes those utilizing the common
γ-chain (γC) family, such as the IL-2 receptor
(IL-2R), IL-4, IL-7R, IL-9R, IL-15R and
IL-21R, those belonging to the IL-3R family,
IL-3R, IL-5R and granulocyte-macrophage col-
ony-stimulating factor receptor (GM-CSFR),
the single-chain receptors for erythropoietin
(EPO), thrombopoietin (TPO), growth hor-
mone (GH), PRL and granulocyte CSF recep-
tor (G-CSF), as well as the class II receptors for
IFNα/β, IFNγ and IL-22 [9–14] . In addition,
several receptor tyrosine kinases can activate
Stat5 proteins, including those for EGF, PDGF
and CSF-1 [15,16]. Furthermore, oncostatin M
has been shown to activate Stat5 through a
heterodimer with gp130 or IL-31 [17,18], whilst
thymic stromal lymphoprotein (TSLP)
achieves this via a heterodimer between TSLPR
and IL-7Rα [19].
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Activation of Stat5 proteins then results in activation of a
range of key genes, depending on the cellular context [20].
These include those encoding Bcl-XL, cyclin D1, Myc, p21,
telomerase and Pim-1 [21–29]. These proteins play key roles in
processes like cell survival and proliferation through effects on
apoptosis and/or the cell cycle. Therefore, perturbation of Stat5
activation has the ability to disrupt these key cellular processes.
Stat5 ablation in mice produced major defects in response to
PRL, GH and a range of hematopoietic cytokines. Stat5a
knockouts were principally defective in PRL-mediated mammo-
poiesis and lactogenesis [30,31], while knockdown of the ortho-
logous zebrafish stat5.1 also produced phenotypes that mir-
rored those of PRL receptor knockdowns [LEWIS ET AL., MANUSCRIPT
SUBMITTED]. Stat5a knockout mice also displayed subtle defects in
T-cell proliferation in response to IL-2 and GM-CSF-induced
proliferation of bone marrow-derived macrophages [31–33]. By
contrast, Stat5b knockouts were phenotypically similar to GH-
deficient mice, with reduced bodyweight, skeleton size and loss
of sexual differentiation responses [31,34,35]. These mice also
demonstrated a decrease in the number of natural killer (NK)
cells and diminished proliferation of T cells in response to IL-2
and IL-15 [36,37]. A subsequent Stat5a/b double-knockout
mouse exhibited exacerbated PRL, GH and much more severe
hematopoietic effects; the latter manifested by an absence of
NK cells, dramatically reduced numbers of pro-B cells and
fewer myeloid colonies [31,36,38]. This suggests some functional
redundancy between Stat5a and Stat5b, especially with respect
to the hematopoietic cytokine receptors. Further studies have
revealed that these mice are best considered as ‘knockdowns’,
forcing a re-evaluation of the role of Stat5. Recently generated
complete Stat5a/b knockouts showed over 99% perinatal
lethality in day 18.5 fetuses with severe hematopoietic defects,
including anemia, leukopenia and substantially reduced num-
bers of both T and B cells [39,40]. These phenotypes were also
largely recapitulated in zebrafish stat5.1 knockdown embryos
[LEWIS ET AL., MANUSCRIPT SUBMITTED].
Stat5 proteins have also been observed to be activated in a
range of disease states, including malignancy. These encompass
cancers of the breast, head and neck, prostate, melanoma, as
well as leukemia and myeloproliferative disorders [25]. The
remainder of this review provides an overview of these dis-
orders, and the role of Stat5 as a diagnostic marker, pathogenic
factor and potential therapeutic target.
Leukemia & myeloproliferative diseases
Normal hematopoiesis is the process whereby hematopoietic
stem cells give rise to multilineage progenitor cells that differenti-
ate into specific subsets of cells; erythroid, myeloid or lymphoid.
This process is highly regulated by cytokines that control check-
points of the cell cycle. Disruption in the regulation of appropri-
ate signaling can lead to uncontrolled expansion of hemato-
poietic cells, leading to disease [3,41,42]. These include a range of
malignancies, including acute myeloid leukemia (AML), acute
lymphoblastic leukemia (ALL), acute promyelocytic leukemia
(APL), chronic lymphocytic leukemia (CLL) chronic myelo-
genous leukemia (CML) and erthyroleukemia, as well as disorders
characterized by an overproliferation of myeloid cell populations,
such as polycythemia vera (PV), essential thrombocythemia
(ET) and idiopathic myelofibrosis (TABLE 2) [3,43–49]. Given the key
role by the Jak-Stat pathway downstream of the raft of cytokines
regulating hematopoiesis, it is not surprising that mutation or
dysregulation of this pathway can contribute to many of these
hematopoietic diseases. In particular, the signal transducers,
Stats, appear to be activated in many of these diseases.
Stat5 as a marker of leukemia
Constitutive activation of Stats has now been identified in pri-
mary samples from a range of malignancies, including leuke-
mias, with Stat1, Stat3 and Stat5 predominantly activated [50].
Stat5 activation is found in patients with AML [51–53], ALL
[50,51], CML, erythroleukemia and megakaryocytic leukemia
[3,5–7]. Importantly, introduction of antisense oligonucleotides
targeting Stat5 proteins into primary CML or AML blasts
decreased proliferation and increased apoptosis, providing
prime face evidence for a pathological role for Stat5 [54]. While
the underlying cause of dysregulated Stat5 activation is not
always known, a clear relationship with an upstream oncogene
has been identified in many cases.
A common illustrative example is the BCR-ABL oncogene.
This results from the translocation t(9;22)(q34;q11), otherwise
known as the Philadelphia chromosome, is the most common
cause of CML. This translocation leads to the fusion of BCR to
Table 1. Cytokines activating Stat5.
Cytokine receptor 
chain
Cytokine
Common γ-chain (γc) IL-2
IL-7
IL-9
IL-15
IL-12
IL-3 family IL-3
IL-5
Granulocyte-macrophage 
colony-stimulating factor
Single-chain receptors Erythropoietin
Thrombopoietin
Growth hormone
Prolactin
Granulocyte colony-stimulating factor
Class II receptors IFNα/β
IFNγ
IL-22
Growth factors Stem cell factor
Flt-3
PDGF
EGF
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the ABL kinase, which increases the tyrosine kinase activity of
ABL and also brings new domains to the ABL kinase including
an SH2-binding site [55]. It has been shown to activate several
downstream pathways, including Stat5, which leads to dysregu-
lated cellular transformation and proliferation [56–58]. It has been
well documented in vitro that BCR-ABL-positive cell lines dis-
play constitutive phosphorylation and subsequent activation of
Stat5, which are not observed in BCR-ABL negative cell lines
[59–62]. A truncated version of Stat5B, which deletes Tyr699 and
the activation domain, is able to dimerize with endogenous
Stat5 and inhibit cell growth in BCR-ABL expressing cells [63].
In addition, this truncated isoform increases cell sensitivity to
cytotoxic agents [63]. This has been borne out in vivo, with Stat5
knockout mice demonstrating reduced sensitivity to the effects
of BCR-ABL [40,64], as are Jak2-deficient fetal liver cells [65],
indicating a role for the Jak2-Stat5 pathway.
Stat5 is also activated by a range of other activated tyrosine
kinases. Tel-Jak2 fusion proteins have been observed in patients
with three different types of leukemia: pre-B cell ALL, T-cell
ALL and atypical CML [66–68]. The fusion (t9;12)(p24;p13)
consists of the oligomerization domain of TEL and both the
kinase and pseudo-kinase domain of Jak2 [66], and displays con-
stitutive activation of its tyrosine kinase activity [68,69], which
leads to the strong constitutive activation of Stat5 [68,70]. Simi-
lar results have also been obtained with TEL-PDGFR. In each
case, the transformation properties have been shown to be
largely dependent on Stat5 [45,71,72]. Stat5 is also activated by
activated forms of various tyrosine kinases (including FLT3 [73])
and in viral oncogenesis (including HTLV-1-mediated T-cell
leukemia [23]). Further emphasizing its role in leukemia, Stat5 is
itself a partner in a leukemic oncogene fusion with retinoic acid
receptor-α (RARα) [74,75], a member of the superfamily of
nuclear hormone receptors [76]. The Stat5b-RARα fusion,
observed in APL, contributes to myeloid maturation arrest by
binding to retinoic acid response elements and augmenting
activation of Stat3 [74,75]. Finally, methylation of the SOCS1
promoter has been observed in 60% of AML patients [77] and
67% of CML patients [78]. Given that Socs1 negatively regu-
lates the Jak-Stat pathway, including Stat5, it is likely that the
reduced expression of Socs1 caused by the methylation may
also contribute to dysregulation of Stat5.
The increased proliferation and survival of hematopoietic
cells in response to Stat5 activation is most probably linked to
transcriptional regulation of downstream targets of Stat5.
However, Stat5 has been shown to repress transcription. This
was demonstrated most recently by the observation that DNA
methylation of the Stat5a promoter is necessary for NPM1-
ALK-mediated transformation, because Stat5a is normally able
to bind to the enhancer region of NPM1-ALK to trigger-selec-
tive suppression of this gene [79]. In addition, the Stat5b-
RARα fusion has been shown to interact with a co-repressor
complex, which inhibits binding of this complex to RARα, in
turn enhancing repressor activity and disrupting hematopoietic
differentiation [80].
Stat5 as a marker of myeloproliferative diseases
Enhanced Stat5 activation has also been observed in several
proliferative diseases. One example of this is PV, a disease
characterized by erythrocytosis, thrombocytosis, leukocytosis
and splenomegaly [81], resulting from cytokine hypersensitiv-
ity, particularly to EPO [82]. It has been postulated that a
somatic point mutation in the pseudo-kinase domain of Jak2
(V617F) is the underlying cause of PV, and also the related ET
and idiopathic myelofibrosis [48,83], because over 95% of PV,
60–70% ET and 50% myelofibrosis patients were found to be
positive for this mutation via allele-specific PCR [47,48,84–88].
Mutation of the pseudo-kinase domain relieves autoinhibition
of Jak activity [89], which subsequently activates the down-
stream Stat5 protein, as observed in cell models and primary
samples [44,47]
A similar result is observed with several other mutations. For
example, truncations of G-CSF receptor lead to hyperprolifera-
tion at the expense of differentiation, with a propensity for
leukemia development [90]. This correlates with sustained activa-
tion of Stat5, which plays a lead role in the hyperproliferation,
with other pathways playing a lesser role [91]. In addition, trun-
cating mutations in the EPO receptor have been linked to
erythrocytosis, in which there is an isolated proliferation of bone
marrow cells of the erythroid lineage due to hypersensitivity to
Table 2. Stat activation in leukemia and 
myeloproliferative diseases.
Disease type Transforming kinase Stat 
activated
Acute myeloid 
leukemia
FLT3
c-Kit
Jak3
v-abl
v-mpl
Stat1, 
Stat3, 
Stat5
Acute lymphoblastic 
leukemia
Tel-Jak2
Tel-PDGFR
Stat1, 
Stat5
Chronic myelogenous 
leukemia
BCR-ABL
p185
p210
Tel-Jak2
Jak2-PCM1
Stat5
Erythroleukemia Stat1, 
Stat5
Megakaryocytic 
leukemia
Stat5
T-cell leukemia HTLV-1
B-cell lymphoma BCR-ABL
p185
p210
Stat5
Myeloproliferative 
disease
Jak2 (V617F)
Tel-Jak2
Tel-PDGFR
Stat5
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EPO [92–94]. These truncations lead to prolonged tyrosine phos-
phorylation of both Jak2 and Stat5 [95], probably due to the loss
of binding of the negative regulator SHP-1. Finally, a point muta-
tion in MPL has been identified in 9% of Jak2 V617F-negative
myelofibrosis patients and leads to increased Stat5 activation [96],
further testifying to the generality of this phenomenon.
Stat5 is also implicated in the myeloproliferation mediated
by a range of mutations involving receptor tyrosine kinases.
These include FGFR1 fusions, which involve translocations of
chromosome band 8p11 [97]. These lead to an aggressive myelo-
proliferative syndrome (EMS), which is characterized by eosi-
nophilia, lymphadenopathy and progression to acute leukemia
[98]. One of the most common translocations is the fusion of
the N-terminal of ZNF198 to the catalytic domain of FGFR1
[99,100]. Many Stats are activated by ZNF198-FGFR1 [101];
however, only the dominant negative version of Stat5 was able
to inhibit the ability of ZNF198-FGFR1 to survive in low
cytokine conditions, due to an essential role in BclXL induction
by the fusion protein [97]. In addition, fusion of the FIP1L1 to
PDGFRα, which results from a deletion on chromosome 4q12
and is found in 56% of patients with idiopathic hyper-
eosinophilic syndrome [102], whilst several novel mutations have
been identified that lead to myeloproliferative disease, includ-
ing an internal tandem repeat involving exons 11 and 12 of
c-Kit found in 7% of childhood AML [103]. 
Mechanisms of pathogenic action
From the aforementioned studies, it is clear that Stat5 may be
considered both a diagnostic and prognostic marker. Modula-
tion of Stat5 in vivo has provided insights into the mechanism
of action in the disease. For example, expression of constitu-
tively active versions of Stat5 alone is sufficient to induce multi-
lineage leukemia in mice [104] and a myeloproliferative disorder
in zebrafish [105]. This is mediated via an enhancement in the
self-renewal of hematopoietic stem cells [106], including the
CD34+ cell population, interestingly with an erythroid bias
[107]. Importantly, Stat5 also appears to mediate long-term
maintenance of leukemic stem and progenitor cells, although
the mutation used in this study could potentially give off-target
effects [108].
At a mechanistic level, it appears that tetrameric forms of
the Stat5 protein are required for pathogenesis, perhaps lead-
ing to more robust activation of certain genes or expansion of
the standard repertoire [104]. Most data are consistent with a
pro-survival role for the protein: for example, by inducing
genes such as BclX [25]. However, there is evidence that it also
plays a role in enhancing/extending cell progression by induc-
ing myc [27,28] and telomerase [29], or by cooperating with loss
of p53 [109]. Interestingly, recent studies also suggest a possible
role outside the nucleus [110], possibly involving PI3K [111]. In
addition, recent studies have demonstrated PI3K-independ-
ent activation of Akt via Stat5 [112]. However, it is important
to recognize that other pathways act in concert with Stat5.
For example, PI3K with BCR-Abl [58], PI3K and PLCγ with
Tel-PDGFR [71], and PI3K and Erk with truncated G-CSF
receptors [91]. 
Stat5 as a marker for therapeutic intervention
Stat5 also serves as both a marker of (successful) therapeutic
intervention, as well as a target in its own right. This includes
first-generation therapies for CML, such as imatinib [55,113,114]
or PD180970 [62], as well as those used against resistant CMLs,
such as dasatinib (BMS-354825) [115] and sorafenib [116]. The
same paradigm is true for the FLT3 inhibitor GTP14564 [117],
the multikinase (FLT3/KIT) inhibitor SU5416 [118], the second-
generation KIT inhibitor PKC412 [119], and even curcumin in
the therapy of HTLV-1-induced T-cell leukemia [120].
Again focusing on the BCR-ABL oncoprotein: a key indica-
tor of the likely success of therapies is their ability to suppress
constitutive Stat5 activation. Imatinib is a potent inhibitor of
BCR-ABL that has proved to be successful with 80% of CML
patients demonstrating complete cytogenetic response after
treatment [121,122]. It targets the ATP binding site of the kinase
[123,124], thereby stabilizing the inactive form of BCR-ABL [121],
inhibiting autophosphorylation and downstream responses,
including Stat5 phosphorylation [123]. However, there is a high
incidence of resistance to this compound, with at least 30 dif-
ferent point mutations identified that block the ability of the
compound to bind the kinase [125,126], while gene amplification
and subsequent overexpression serve as an alternate route for
generating resistance [125]. As a result, a second generation of
inhibitors has been created [127–129]. This includes BMS-
354825, which is 100-times as potent, is active against most
resistant BCR-ABL mutants in vitro [128] and also blocks Stat5
signaling, inhibits cell proliferation and induces apoptosis [115].
There are many ongoing studies to identifying specific pan-
Jak2 inhibitors based on the molecular structure of the Jak2
and Jak3 kinase domains, and they are refining the original
tyrosine phosphorylation inhibitors [130,131]. In addition, there
are currently screens underway in an attempt to identify spe-
cific inhibitors of Jak2V617F, which will provide an optimal
therapeutic as only the disease allele will be targeted [132].
Underpinning the key role of Stat5 is the recent realization
that one mechanism by which cells lose sensitivity to imatinib
is to utilize alternate pathways to activate the protein, such as
via secretion of GM-CSF and subsequent autocrine activation
[133]. Moreover, targeting Stat5 by RNAi leads to a reduction
in proliferation to the same extent as BCR-ABL RNAi in cell
culture, and could reduce colony formation from primary
CML [134].
Expert commentary
Leukemia poses a significant health burden, with approxi-
mately 44,000 new cases diagnosed in the USA in 2007, strik-
ing more than 10-times as many children as adults, while
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MPDs present serious concerns for an older cohort of
patients. Current advances in both basic science and pharma-
ceutical technologies have seen rapid advances in our under-
standing of both leukemia and MPD at the molecular level in
recent years. In particular, these insights have led to the gener-
ation of drugs to help combat these diseases, including the tai-
loring of therapies to specific patients depending on their
molecular profile. Thus, we have already seen the revolution
of specific kinase inhibitors, such as to BCR-ABL, and now
second-generation compounds that overcome the problems of
resistance. However, with so many molecular changes now
known to contribute to these diseases, and the increasing inci-
dence of resistance to these drugs, more specific therapies are
required. Activation of Stat5 has been demonstrated in a large
number of leukemias and MPDs, and thus represents a useful
diagnostic marker of both leukemia and MPD. Moreover,
since Stat5 is a point of common convergence for a range of
different pathologic alterations, it is also a sensible therapeutic
target for these diseases. 
Five-year view
Over the next 5 years, we anticipate that Stat5 (and other Stat
proteins) will become a key diagnostic and prognostic marker.
It will be increasingly targeted for therapeutic intervention.
This may be indirect, by targeting molecules that either medi-
ate its effects or regulate it. For example, antibodies to CD44
(a key target of Stat5 downstream of BCR-ABL) attenuates
CML-like leukemia in both human cell lines and murine
recipients [135,136]. Alternatively, monoclonal antibodies or
antagonists directed against receptors lying upstream of Stat5
may be used, especially given the success of an IL-6 super-
antagonist in blocking the constitutive activation of Stat3,
inducing apoptosis and inhibiting growth in a myeloma cell
line and a patient with plasma cell leukemia [137–139]. Tocilizu-
mab, a humanized murine monoclonal antibody, was recently
released, which displaces IL-6 from the IL-6Rα complex at
extremely high affinity and will be extensively utilized for
inflammatory diseases in the near future [140,141]. In addition,
inhibitors of both tyrosine and serine/threonine kinases, which
phosphorylate and thus activate Stat5 (e.g., Jak kinases) are
likely to play an important therapeutic role. Finally, down-
stream regulators of Stat5, including Socs and PIAS proteins
or the tyrosine phosphatases SHP-1 and SHP-2, could also be
targeted.
However, direct targeting of Stat5 remains an exciting possi-
bility. We have already discussed the successful targeting of
Stat5 RNAi in a conditional cell culture model to inhibit
BCR-ABL-dependent cell proliferation in a dose-dependent
manner [134]. Another candidate to directly block Stat5 activity
would be a SH2-like peptide, which is able to recognize and
bind phosphotyrosine residues of Stats [142,143]. This approach
has again been successfully demonstrated for Stat3 with the use
of an SH2 domain-binding phosphotyrsol (PY*LKTK), which
was able to block Stat3 DNA binding activity and subsequent
gene regulation both in vitro and in vivo [142]. Alternatively,
antisense oligodeoxyribonucleic acids have been shown to suc-
cessfully target Stat3 to reduce proliferation of leukemia and
lymphoma cells [144], and thus are worth considering for Stat5.
Short double-stranded decoy oligonucleotides are another
alternative [144]. However, targeting transcription factors intra-
cellularly remains a challenge, with problems of delivery and
control of off-target effects representing key issues. This sug-
gests that it may not be realistic that specific Stat5 inhibitors
will be sufficiently developed for therapeutic use within the
next 5 years – although certainly in the 5 years after that.
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Key issues
• Stat5 is normally transiently activated by a variety of cytokines, 
with a role in hematopoiesis.
• Stat5 proteins are often constitutively activated in leukemias 
and myeloproliferative diseases.
• Stat5 is activated by known leukemic oncogenes, such as 
BCR-ABL and Tel-Jak2, or known mediators of 
myeloproliferation, including mutants of Jak2 EPOR and G-CSFR.
• The ability to suppress activation of Stat5 correlates well with 
the success of therapeutics in treating leukemias and 
myeloproliferative diseases.
• Specific targeting Stat5 represents an attractive therapeutic 
strategy for multiple disease states.
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